FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:2249-2250 May 29, 2003 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Lalezari, J. P. Related Article by Lazzarin, A. PubMed Citation

Two studies reported in this issue of the Journal^1,2 provide heartening news of the success of a new antiretroviral drug in decreasing plasma human immunodeficiency virus (HIV) RNA levels in patients for whom the available combination antiretroviral regimens are no longer effective. These reports are especially noteworthy in that they describe the first controlled trials of the fusion inhibitor enfuvirtide, a representative of a new class of drugs that prevent the entry of HIV type 1 (HIV-1) into the target cells of the host.³ Enfuvirtide specifically prevents the fusion of the HIV-1 transmembrane (gp41) glycoprotein with the CD4 receptor of . . . [Full Text of this Article]

Source Information

From Miriam Hospital, Providence, R.I.

This article has been cited by other articles:

• Witvrouw, M., Fikkert, V., Hantson, A., Pannecouque, C., O'Keefe, B. R., McMahon, J., Stamatatos, L., de Clercq, E., Bolmstedt, A. (2005). Resistance of Human Immunodeficiency Virus Type 1 to the High-Mannose Binding Agents Cyanovirin N and Concanavalin A. J. Virol. 79: 7777-7784 [Abstract] [Full Text]  
• (2003). A New Class of Drugs for HIV Treatment. Journal Watch Dermatology 2003: 8-8 [Full Text]  
• (2003). A New Class of Drugs for HIV Treatment. JWatch General 2003: 5-5 [Full Text]